DOCSLIB.ORG

Leu2010170.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leu2010170.Pdf Leukemia (2010) 24, 1686–1699 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 www.nature.com/leu REVIEW Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies N Chapuis1,2,3, J Tamburini1,2,4, AS Green1,2, L Willems1,2,4, V Bardet1,2,3, S Park1,2,4, C Lacombe1,2,3, P Mayeux1,2 and D Bouscary1,2,4 1De´partement d’Immunologie-He´matologie, Institut Cochin, Universite´ Paris Descartes, CNRS, UMR8104, Paris, France; 2INSERM, U1016, Paris, France; 3Service d’He´matologie Biologique, Hoˆpital Cochin, AP-HP, Paris, France and 4Service de Me´decine Interne-UF d’He´matologie, Hoˆpital Cochin, Paris, France Mammalian target of rapamycin (mTOR) is a protein kinase Structure of mTOR implicated in the regulation of various cellular processes, including those required for tumor development, such as the mTOR is a serine/threonine kinase that belongs to the phospho- initiation of mRNA translation, cell-cycle progression and cellular proliferation. In a wide range of hematological malig- inositide 3-kinase (PI3K)-related kinase family and is ubiqui- nancies, the mTORC1 signaling pathway has been found to be tously expressed in mammalian cells. mTOR was first described deregulated and has been designed as a major target for tumor in yeast as the cellular target of rapamycin, an immunosuppres- therapy. Given that pre-clinical studies have clearly established sive agent first identified as a product of the bacterium the therapeutic value of mTORC1 inhibition, numerous clinical Streptomyces hygroscopicus.1 The mTOR protein comprises trials of rapamycin and its derivates (rapalogs) are ongoing a C-terminal catalytic domain, an FRB domain (FKBP-12- for treatment of these diseases. At this time, although disease stabilization and tumor regression have been observed, rapamycin binding domain) that facilitates the binding of objective responses in some tumor types have been modest. FKBP-12(FK506 binding protein 12)/rapamycin complexes, a Nevertheless, some of the mechanisms underlying cancer-cell C-terminal negative regulatory domain, 20 or more N-terminal resistance to rapamycin have now been described, thereby HEAT repeats (Huntingtin, EF3, A subunit of PP2A and TOR) that leading to the development of new strategy to efficiently target enable protein–protein interactions and FRAP-ATM-TRRAP mTOR signaling in these diseases. In this review, we discuss (FAT) domains that modulate catalytic activity.2 It is now known the rationale for using mTOR inhibitors as novel therapies for a variety of hematological, malignancies with a focus on that mTOR resides in at least two distinctive multi-protein promising new perspectives for these approaches. complexes, mTORC1 and mTORC2, which are distinguished by Leukemia (2010) 24, 1686–1699; doi:10.1038/leu.2010.170; their partner proteins, their substrate specificities and their published online 12 August 2010 differential sensitivity to rapamycin. Keywords: mTORC1; mTORC2; PI3K/Akt; hematological malignancies; rapalogs; TORKinhib mTORC1 Introduction mTORC1 is usually defined as a complex of mTOR and raptor (regulatory-associated protein of mTOR). However, mTORC1 The mammalian target of rapamycin (mTOR) is a key regulator also contains mLST8 (also known as GbL), the proline-rich of various cellular processes needed for growth, cell-cycle 3 Akt/PKB substrate 40kDa (PRAS40) and the recently identified progression and cell metabolism. The mTOR pathway functions dishevelled, egl-10, pleckstrin (DEP)-domain-containing mTOR- as a sensor to ensure an appropriate nutritional state to support 4 interacting protein (deptor). The mTORC1 complex is generally cell development. The blockade of the mTOR signaling can thus inhibited by rapamycin (Sirolimus) and its analogs (CCI-779, prevent cells from responding to extracellular signals transduced RAD001 and AP23573), which are referred to as rapalogs. In from growth factor receptors under conditions of energy and/or most cell types, rapalogs specifically induce the allosteric nutrient deficiency. Conversely, mTOR activation promotes cell repression of mTORC1 activity through their association with growth and proliferation under conditions of energy and nutrient 5 FKBP-12. These FKBP-12/rapamycin complexes bind mTOR in a repletion, through an increase in ribosomal biogenesis and 6 unique region known as the FKBP-rapamycin-binding domain, protein synthesis. As mTOR activity is frequently observed to be 7,8 resulting in the dissociation of mTOR from raptor. The FKBP- deregulated in cancer, including hematological malignancies, 12/rapamycin complexes thus fuction as allosteric inhibitors of this kinase represents a highly attractive target for novel cancer mTORC1 without directly affecting mTOR catalytic activity. therapies. In this review, we discuss the current model for the The exact functions of most mTOR-interacting proteins within mTOR signaling pathway and then focus on the mechanisms the mTORC1 complex remain unclear. Nevertheless, the underlying its deregulation in hematological malignancies. activity of mTORC1 is dependent upon raptor, which functions Finally, we explore the value of targeting mTOR as a future 7,9 as a scaffold for recruiting mTORC1 substrates. The mLST8 anti-cancer therapy. protein lacks kinase activity, but is also required for proper mTOR activity.10 PRAS40 is a negative regulator of mTORC1 Correspondence: Professor D Bouscary, De´partement d’Immunology- and blocks the interaction between mTOR and its substrates. ´ ´ Hematology, Institut Cochin, Universite Paris Descartes, 22 rue Upon phosphorylation by Akt, PRAS40 dissociates from Me´chain, Paris 75014, France. E-mail: [email protected] or [email protected] mTORC1 and binds 14.3.3 proteins, which release mTORC1 11 Received 17 April 2010; revised 7 June 2010; accepted 29 June 2010; activity. Recently a new protein, deptor, has been identified as published online 12 August 2010 an mTOR-interacting protein4 and has been found to negatively Perspectives on inhibiting mTOR N Chapuis et al 1687 regulate mTORC1. Accordingly, the loss of deptor expression (Ras homolog enriched in brain). The active GTP-bound form leads to the activation of mTORC1 signaling.4 of Rheb directly interacts with mTORC1 and stimulates its activity. Accordingly, through its GTPase-activating protein activity TSC1/2 maintains the binding of Rheb to Guanosine mTORC2 diphosphate and suppresses mTORC1 activity (Figure 1). mTORC2 comprises mLST8 and deptor, which are also found Conversely, the activation of Akt downstream of PI3K and in mTORC1, but also specifically contain mSIN1, rictor of the extra-cellular regulated kinase 1/2 (ERK1/2) leads to (rapamycin insensitive companion of mTOR) and protor-1. the inhibition of TSC2 by phosphorylation at its S939/S1462 and Moreover, in contrast to mTORC1, mTORC2 is usually S540/S664 residues, respectively, which leads, therefore, to rapamycin-insensitive,12,13 although some evidence has sug- mTORC1 activation.17–19 gested that prolonged treatment with rapamycin may inhibit its activity towards Akt, depending on the cell type. The induction by rapamycin of an imbalance in the mTORC2 constitution Adenosine mono phosphate-activated protein has been suggested to explain this effect.14,15 Finally, deptor kinase (AMPK) also negatively regulates mTOR activity in mTORC2.4 Energy metabolism has been found to regulate mTOR through the AMPK. AMPK, which is a sensor for cellular energy, responds to the cellular AMP/ATP (adenosine triphosphate) ratio and is Upstream mechanisms leading to mTORC1 activation activated by metabolic stresses that inhibit ATP production (for example, hypoxia and glucose deprivation) or that stimulate ATP Growth factor receptors consumption. Under energy stress conditions, AMPK activates The mTORC1 pathway can be activated either by extracellular TSC2 by phopshorylation on T1227 and S1345,whichleads, signals transduced from growth factor receptors or by modifica- therefore, to the repression of mTORC1 activity.20 tions of the metabolic status of the cell.16 Downstream of growth factor receptors, extracellular signals converge at the tuberous sclerosis complex (TSC1/TSC2/Rheb) axis. TSC1/2 comprises The amino acid pathway hamartin (TSC1) and tuberin (TSC2) and exhibits a GTPase- From a deterministic point of view, it is easy to understand that activating protein function toward the Ras-related GTPase Rheb the rate of protein synthesis is directly dependent upon amino Amino Energy Growth factors ? acids (ATP) TKR PIP2 PIP3 308 P IRS T P S473 PI3K PDK1 P Akt AMPK P P P TSC1 TSC2 ERK1/2 Feedback PRAS40 Protor inhibition mLST8 mSIN1 mTOR Rheb GTP mTOR Deptor mLST8 mTORC1 Raptor Deptor Rictor mTORC2 T389 65 37/46 S T P RhoA P P P SGK P P70S6K 70 4E-BP1 T PKCα P Cytoskelatal Protein eIF4E eIF4G P organization synthesis NDRG1 P Paxillin 4E-BP1 Cap-dependent translation eIF4E Cell survival Figure 1 The mTOR signaling pathway. Red lines indicate the different mechanisms of mTOR activation. Abbreviations: AMPK, AMP-activated kinase; deptor, DEP-domain-containing mTOR interacting protein; 4E-BP1, eIF4E-binding protein 1; eIF, eukaryotic initiation factors; ERK1/2, extra-cellular regulated kinase 1/2; FKBP12, FK506 binding protein 12; IRS, Insulin receptor substrates; mLST8, mammalian lethal with Sec13 protein 8; mTORC, mammalian target of rapamycin complex; NDRG1, N-Myc downstream regulated gene-1; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol bisphosphate; PIP3,
Load more

Recommended publications
  • The Application of a Characterized Pre-Clinical
    THE APPLICATION OF A CHARACTERIZED PRE-CLINICAL GLIOBLASTOMA ONCOSPHERE MODEL TO IN VITRO AND IN VIVO THERAPEUTIC TESTING by Kelli M. Wilson A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland March, 2014 ABSTRACT Glioblastoma multiforme (GBM) is a lethal brain cancer with a median survival time (MST) of approximately 15 months following treatment. A serious challenge facing the development of new drugs for the treatment of GBM is that preclinical models fail to replicate the human GBM phenotype. Here we report the Johns Hopkins Oncosphere Panel (JHOP), a panel of GBM oncosphere cell lines. These cell lines were validated by their ability to form tumors intracranially with histological features of human GBM and GBM variant tumors. We then completed whole exome sequencing on JHOP and found that they contain genetic alterations in GBM driver genes such as PTEN, TP53 and CDKN2A. Two JHOP cell lines were utilized in a high throughput drug screen of 466 compounds that were selected to represent late stage clinical development and a wide range of mechanisms. Drugs that were inhibitory in both cell lines were EGFR inhibitors, NF-kB inhibitors and apoptosis activators. We also examined drugs that were inhibitory in a single cell line. Effective drugs in the PTEN null and NF1 wild type cell line showed a limited number of drug targets with EGFR inhibitors being the largest group of cytotoxic compounds. However, in the PTEN mutant, NF1 null cell line, VEGFR/PDGFR inhibitors and dual PIK3/mTOR inhibitors were the most common effective compounds.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Confidential Clinical study protocol number: J1228 Page 1 Version Date: May 7, 2018 IRB study Number: NA_00067315 A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin’s Lymphoma Principal Investigator: Douglas E. Gladstone, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1650 Orleans Street, CRBI-287 Baltimore, MD 21287 Phone: 410-955-8781 Fax: 410-614-1005 Email: [email protected] IRB Protocol Number: NA_00067315 Study Number: J1228 IND Number: EXEMPT Novartis Protocol Number: CRAD001NUS157T Version: May 7, 2018 Co-Investigators: Jonathan Powell 1650 Orleans Street, CRBI-443 Phone: 410-502-7887 Fax: 443-287-4653 Email: [email protected] Richard Jones 1650 Orleans Street, CRBI-244 Phone: 410-955-2006 Fax: 410-614-7279 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 2 Version Date: May 7, 2018 IRB study Number: NA_00067315 Satish Shanbhag Johns Hopkins Bayview Medical Center 301 Building, Suite 4500 4940 Eastern Ave Phone: 410-550-4061 Fax: 410-550-5445 Email: [email protected] Statisticians: Gary Rosner Phone: 410-955-4884 Email: [email protected] Marianna Zahurak Phone: 410-955-4219 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 3 Version Date: May 7, 2018 IRB study Number: NA_00067315 Table of contents Table of contents ......................................................................................................................... 3 List of abbreviations
    [Show full text]
  • LEUSTATIN (Cladribine) Injection Should Be Administered Under the Supervision of a Qualified Physician Experienced in the Use of Antineoplastic Therapy
    LEUSTATIN (cladribine) Injection For Intravenous Infusion Only WARNING LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies. DESCRIPTION LEUSTATIN (cladribine) Injection (also commonly known as 2-chloro-2΄-deoxy- β -D-adenosine) is a synthetic antineoplastic agent for continuous intravenous infusion. It is a clear, colorless, sterile, preservative-free, isotonic solution. LEUSTATIN Injection is available in single-use vials containing 10 mg (1 mg/mL) of cladribine, a chlorinated purine nucleoside analog. Each milliliter of LEUSTATIN Injection contains 1 mg of the active ingredient and 9 mg (0.15 mEq) of sodium chloride as an inactive ingredient. The solution has a pH range of 5.5 to 8.0. Phosphoric
    [Show full text]
  • Synthesis of Ribavirin, Tecadenoson, and Cladribine by Enzymatic Transglycosylation
    catalysts Article Synthesis of Ribavirin, Tecadenoson, and Cladribine by Enzymatic Transglycosylation 1, 2 2,3 2 Marco Rabuffetti y, Teodora Bavaro , Riccardo Semproli , Giulia Cattaneo , Michela Massone 1, Carlo F. Morelli 1 , Giovanna Speranza 1,* and Daniela Ubiali 2,* 1 Department of Chemistry, University of Milan, via Golgi 19, I-20133 Milano, Italy; marco.rabuff[email protected] (M.R.); [email protected] (M.M.); [email protected] (C.F.M.) 2 Department of Drug Sciences, University of Pavia, viale Taramelli 12, I-27100 Pavia, Italy; [email protected] (T.B.); [email protected] (R.S.); [email protected] (G.C.) 3 Consorzio Italbiotec, via Fantoli 15/16, c/o Polo Multimedica, I-20138 Milano, Italy * Correspondence: [email protected] (G.S.); [email protected] (D.U.); Tel.: +39-02-50314097 (G.S.); +39-0382-987889 (D.U.) Present address: Department of Food, Environmental and Nutritional Sciences, University of Milan, y via Mangiagalli 25, I-20133 Milano, Italy. Received: 7 March 2019; Accepted: 8 April 2019; Published: 12 April 2019 Abstract: Despite the impressive progress in nucleoside chemistry to date, the synthesis of nucleoside analogues is still a challenge. Chemoenzymatic synthesis has been proven to overcome most of the constraints of conventional nucleoside chemistry. A purine nucleoside phosphorylase from Aeromonas hydrophila (AhPNP) has been used herein to catalyze the synthesis of Ribavirin, Tecadenoson, and Cladribine, by a “one-pot, one-enzyme” transglycosylation, which is the transfer of the carbohydrate moiety from a nucleoside donor to a heterocyclic base. As the sugar donor, 7-methylguanosine iodide and its 20-deoxy counterpart were synthesized and incubated either with the “purine-like” base or the modified purine of the three selected APIs.
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Recent Topics on the Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 29 May 2019 doi:10.20944/preprints201905.0358.v1 Peer-reviewed version available at Int. J. Mol. Sci. 2019, 20, 3210; doi:10.3390/ijms20133210 1 of 39 1 Review 2 Recent topics on the mechanisms of 3 immunosuppressive therapy-related neurotoxicities 4 Wei Zhang 1, Nobuaki Egashira 1,2,* and Satohiro Masuda 1,2 5 1 Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, 6 Kyushu University, Fukuoka 812-8582, Japan 7 2 Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan 8 * Correspondence: [email protected], Tel.: 81-92-642-5920 9 Abstract: Although transplantation procedures have been developed for patients with end-stagec 10 hepatic insufficiency or other diseases, allograft rejection still threatens patient health and lifespan. 11 Over the last few decades, the emergence of immunosuppressive agents, such as calcineurin 12 inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors, have strikingly 13 increased graft survival. Unfortunately, immunosuppressive agent-related neurotoxicity is 14 commonly occurred in clinical situations, with the majority of neurotoxicity cases caused by CNIs. 15 The possible mechanisms whereby CNIs cause neurotoxicity include: increasing the permeability 16 or injury of the blood-brain barrier, alterations of mitochondrial function, and alterations in 17 electrophysiological state. Other immunosuppressants can also induce neuropsychiatric 18 complications. For example, mTOR inhibitors induce seizures; mycophenolate mofetil induces 19 depression and headache; methotrexate affects the central nervous system; mouse monoclonal 20 immunoglobulin G2 antibody against cluster of differentiation 3 also induces headache; and 21 patients using corticosteroids usually experience cognitive alteration.
    [Show full text]
  • ATC/DDD Classification
    WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/ DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information. ATC/DDD classification (temporary) The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2018. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2019. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2020 version of the ATC/DDD Index. New ATC 5th level codes ATC level name/INN ATC code acalabrutinib L01XE51 amenamevir J05AX26 amlodipine and celecoxib C08CA51 arginine and lysine V03AF11 atorvastatin and omega-3 fatty acids C10BA08 baloxavir marboxil J05AX25 betrixaban B01AF04 brolucizumab S01LA06 cemiplimab L01XC33 crizanlizumab B06AX01 daclatasvir, asunaprevir and beclabuvir J05AP58 darolutamide L02BB06 elagolix H01CC03 elbasvir J05AP10 entinostat L01XX64 Continued 5 51 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018 New ATC 5th level codes (continued)
    [Show full text]
  • Cladribine Injection
    PRODUCT MONOGRAPH PrCLADRIBINE INJECTION Solution for Intravenous Injection 1 mg/mL USP Antineoplastic / Chemotherapeutic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 June 9, 2015 Toronto, ON M9W 0C8 Control No.: 181078 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 10 DOSAGE AND ADMINISTRATION ..................................................................................... 11 OVERDOSAGE ....................................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 14 STORAGE AND STABILITY ................................................................................................
    [Show full text]
  • Original Article Treatment of Hairy Cell Leukemia with Cladribine
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library Annals of Oncology 13: 1641–1649, 2002 Original article DOI: 10.1093/annonc/mdf272 Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study A. von Rohr1*, S.-F. H. Schmitz2, A. Tichelli3, U. Hess4, D. Piguet5, M. Wernli6, N. Frickhofen7, G. Konwalinka8, G. Zulian9, M. Ghielmini10, B. Rufener2, C. Racine1, M. F. Fey1, T. Cerny1, D. Betticher1 & A. Tobler11 On Behalf of the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland 1Institute of Medical Oncology, Inselspital, Bern; 2SIAK Coordinating Center, Bern; 3Division of Hematology, Kantonsspital, Basel; 4Department of Internal Medicine, Kantonsspital, St Gallen; 5Department of Internal Medicine, Hôpital des Cadolles, Neuchâtel; 6Department of Internal Medicine, Kantonsspital, Aarau, Switzerland; 7Department of Internal Medicine, University Hospital, Ulm, Germany; 8Department of Internal Medicine, University Hospital, Innsbruck, Austria; 9Department of Internal Medicine, University Hospital, Geneva; 10Oncology Institute of Southern Switzerland, Bellinzona; 11Central Hematology Laboratory, University Hospital, Bern, Switzerland Received 8 January 2002; revised 11 April 2002; accepted 24 April 2002 Background: To assess the activity and toxicity of 2-chlorodeoxyadenosine (cladribine, CDA) given by subcutaneous bolus injections to patients with hairy cell leukemia (HCL). Patients and methods: Sixty-two eligible patients with classic or prolymphocytic HCL (33 non- pretreated patients, 15 patients with relapse after previous treatment, and 14 patients with progressive disease during a treatment other than CDA) were treated with CDA 0.14 mg/kg/day by subcutaneous bolus injections for five consecutive days.
    [Show full text]
  • Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients
    Article Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients | Sunil V. Badve,*†‡ Elaine M. Pascoe,* Michael Burke,§ Philip A. Clayton, ¶ Scott B. Campbell,§ Carmel M. Hawley,*§ | Wai H. Lim,** Stephen P. McDonald, ¶ Germaine Wong,†† and David W. Johnson*§ Abstract Background and objectives Emerging evidence from recently published observational studies and an individual – *Australasian Kidney patient data meta analysis shows that mammalian target of rapamycin inhibitor use in kidney transplantation Trials Network, School is associated with increased mortality. Therefore, all-cause mortality and allograft loss were compared of Medicine, between use and nonuse of mammalian target of rapamycin inhibitors in patients from Australia and New University of Zealand, where mammalian target of rapamycin inhibitor use has been greater because of heightened skin Queensland, cancer risk. Brisbane, Australia; †Department of Nephrology, Design, setting, participants, & measurements Our longitudinal cohort study included 9353 adult patients who St. George Hospital, underwent 9558 kidney transplants between January 1, 1996 and December 31, 2012 and had allograft survival Sydney, Australia; ‡ $1 year. Risk factors for all-cause death and all–cause and death–censored allograft loss were analyzed by Renal and Metabolic Division, The George multivariable Cox regression using mammalian target of rapamycin inhibitor as a time-varying covariate. fi Institute for Global Additional analyses evaluated mammalian target of rapamycin inhibitor use at xed time points of baseline and Health, Sydney, 1year. Australia; §Department of Results Patients using mammalian target of rapamycin inhibitors were more likely to be white and have a history Nephrology, Princess Alexandra Hospital, of pretransplant cancer. Over a median follow-up of 7 years, 1416 (15%) patients died, and 2268 (24%) allografts Brisbane, Australia; | were lost.
    [Show full text]
  • Targeting Mtor Signaling Overcomes Acquired Resistance to Combined BRAF and MEK Inhibition in BRAF-Mutant Melanoma
    www.nature.com/onc Oncogene ARTICLE OPEN Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma Beike Wang1,11, Wei Zhang1,11, Gao Zhang 2,10,11, Lawrence Kwong3, Hezhe Lu4, Jiufeng Tan2, Norah Sadek2, Min Xiao2, Jie Zhang 5, 6 2 2 2 2 5 7 6 Marilyne Labrie , Sergio Randell , Aurelie Beroard , Eric Sugarman✉ , Vito W. Rebecca✉ , Zhi Wei , Yiling Lu , Gordon B. Mills , Jeffrey Field8, Jessie Villanueva2, Xiaowei Xu9, Meenhard Herlyn 2 and Wei Guo 1 © The Author(s) 2021 Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase protein array (RPPA), we aim to understanding the role of the mTORC1 signaling pathway, a center node of intracellular signaling network, in mediating drug resistance of BRAF-mutant melanoma to the combination of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) therapy. The mTORC1 signaling pathway is initially suppressed by BRAFi and MEKi combination in melanoma but rebounds overtime after tumors acquire resistance to the combination therapy (CR) as assayed in cultured cells and PDX models. In vitro experiments showed that a subset of CR melanoma cells was sensitive to mTORC1 inhibition. The mTOR inhibitors, rapamycin and NVP-BEZ235, induced cell cycle arrest and apoptosis in CR cell lines. As a proof-of-principle, we demonstrated that rapamycin and NVP-BEZ235 treatment reduced tumor growth in CR xenograft models. Mechanistically, AKT or ERK contributes to the activation of mTORC1 in CR cells, depending on PTEN status of these cells.
    [Show full text]
  • Cladribine (Leustatin®) Pronounced: “KLAD-Rih-BEAN”
    Cladribine Chemotherapy: Cladribine (Leustatin®) Pronounced: “KLAD-rih-BEAN” How drug is given: By vein (IV) Purpose: To treat hairy cell leukemia, non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and other cancers Things that may occur during or within hours of treatment • Facial flushing (warmth or redness of the face), itching, or a skin rash could occur. These symptoms are due to an allergic response and should be reported to your cancer care team right away. Things that may occur days to weeks after drug is given • Your blood cell counts may drop. This is known as bone marrow suppression. This includes a decrease in your: o Red blood cells, which carry oxygen in your body to help give you energy o White blood cells, which fight infection in your body o Platelets, which help clot the blood to stop bleeding This may happen 7 to 14 days after the drug is given and then blood counts should return to normal. If you have a fever of 100.5°F (38°C) or higher, chills, a cough, or any bleeding problems, tell your cancer care team right away. • Some patients may feel very tired, also known as fatigue. You may need to rest or take naps more often. Mild to moderate exercise can also be helpful in maintaining your energy. • Some patients may have mild nausea. You may be given medicine to help with this. • You may get a headache. Please talk to your doctor or nurse about what you can take for this. • In rare cases, nerves can be affected by this medicine.
    [Show full text]